Wednesday August 12, 2020

CF drug maker offers treatment at surcharge of €23,000 per patient

Cystic Fibrosis Ireland boss says ‘no justification for price differential’ with Britain

Susan Mitchell

Deputy Editor and Health Editor

26th June, 2016
Cystic Fibrosis drug called Orkambi

The manufacturer of the breakthrough Cystic Fibrosis drug called Orkambi proposed charging €23,000 more per person for its drug in Ireland compared with England.

Vertex offered a €158,000 price tag per patient per year to the Irish health service in the submission it made a few months ago.

Vertex then offered England’s National Health Service (NHS) a list price of €135,000 (£104,000) per patient per year.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

2 Yearly



Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Irish doctors will not use the term ‘fully reversible’ in future, following a change in Britain’s NHS guidance on hormone treatment for transgender children

Aaron Rogan | 3 days ago

The founder of the expert group EndCoronavirus says New Zealand’s zero tolerance model is the only option against the virus

Rachel Lavin | 3 days ago

Unicef adviser says ‘special effort’ must be made to catch children up on immunisations missed due to Covid-19

Rachel Lavin | 3 days ago